Esm1 and Stc1 as Angiogenic Factors Responsible for Protective Actions of Adipose-Derived Stem Cell Sheets on Chronic Heart Failure After Rat Myocardial Infarction

Abstract

he efficacy of pharmacological and surgical treatments for chronic heart failure after myocardial infarction (MI) is limited. Cell-based regenerative therapy (cell transplantation) improved the blood supply to the damaged heart, and minimized the area of infarc-tion. 1-3 These beneficial effects are mediated, in part, by cytokines, such as hepatocyte growth factor (HGF) and Editorial p ????

Identification and Interaction Analysis of Molecular Markers in Myocardial Infarction by Integrated Bioinformatics Analysis

“…Lin et al [40] and Wuest et al [41] found that the role of IL1RL1 and ALOX15B in coronary artery disease. Research have shown that SERPINA3 [42], GPR78 [43] and ESM1 [44] plays a significant role in MI progression. Expression of the SCGN (secretagogin, EF-hand calcium binding protein) gene plays a role in the development of diabetes mellitus [45], but this genes might be novel target for MI.…”

“…PLA2G2A [61], CCL23 [62], CD53 [63], TREML4 [64], TREM2 [65], CD180 [66], HPSE (heparanase) [67], CELA2A [68], TNFRSF4 [69], AMBP (alpha-1-microglobulin/bikunin precursor) [70], SOX18 [71], PANX2 [72], RSPO2 [73], COMP (cartilage oligomeric matrix protein) [74], ASGR1 [75] and NOXA1 [76] are involved in progression of atherosclerosis. A previous study reported that S100A9 [77], ADORA3 [78], IL1R2 [79], FPR1 [80], CCL20 [81], CD163 [82], S100A8 [83], TLR2 [84], HAS2 [85], PTX3 [86], TIMP4 [87], AREG (amphiregulin) [88], LBP (lipopolysaccharide binding protein) [89], IL18R1 [90], ALOX5AP [91], RETN (resistin) [92], F13A1 [93], FPR2 [94], SAA1 [95], FLT3 [96], AQP4 [97], FCER1G [98], CCL18 [99], HP (haptoglobin) [100], CDK1 [101], SLC7A11 [102], CFTR (CF transmembrane conductance regulator) [103], F8 [104], STC1[44], IL18RAP [90], TIMP3 [105], PDE4D [106], CYP4A11 [107], SCN10A [108], APOB (apolipoprotein B) [109], ACE (angiotensin I converting enzyme) [110], PENK (proenkephalin) [111], HSPB6 [112], TLR9 [113], EGR1 [114], CACNG8 [115], FOXD3 [116], DBH (dopamine beta-hydroxylase) [117], FOXP3 [118], GLP1R [119], IL34 [120], CCN1 [121], ADRA2A [122], BGN (biglycan) [123], NOS2 [124], AGRN (agrin) [125], DRD1 [126], GNB3 [127], EGR2 [128], MDK (midkine) [129], NOTCH3 [130], AZIN2 [131], NOTCH1 [132], LOX...…”

Future of Therapeutic Angiogenesis Using Adipose-Derived Stem Cells in the Cardiovascular Field

“…12 Watanabe et al have created dual reporter transgenic rats expressing green fluorescence protein and luciferase and fabricated ADSC sheets using a temperature-responsive culture dish. 13 When these ADSC sheets were implanted in the rat model of myocardial infarction, tracking of luciferase signals revealed that the implanted ADSC sheets survived for ≥2 weeks after implantation. After ADSC sheet implantation, there was an increase in microvessels in the ischemic area, and cardiac function after myocardial infarction improved.…”

“…After ADSC sheet implantation, there was an increase in microvessels in the ischemic area, and cardiac function after myocardial infarction improved. 13 Thus, ADSC sheet implantation may allow cells to survive for a relatively long time and for them to perform their functions.…”

“…11 Watanabe et al identified endothelial cell-specific molecule 1 (ESM1) and stanniocalcin 1 (Stc1) as new angiogenic growth factors, in addition to previously reported angiogenic growth factors (e.g., VEGF, HGF, and bFGF), secreted from ADSCs. 13 Because the addition of recombinant ESM1 and Stc1 proteins to vascular endothelial cells induces tube formation comparable with that induced by VEGF, these factors appear to have a potent proangiogenic action. Some reports indicate that ADSC implantation is more effective in improving cardiac function after myocardial infarction than the use of other stem cells, such as bone marrow-derived stem cells.…”